{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:36:07Z","timestamp":1790620567297,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The purpose of this study was to estimate the overall survival (OS) in real-world clinical practice in patients with metastatic breast cancer (MBC) and visceral metastases (liver or lung) treated in the third-line setting with eribulin, gemcitabine or capecitabine overall and in the major clinical categories of MBC (TNBC, HR+\/HER2\u2212, and HER2+).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective, observational study was conducted with de-identified patient electronic health records from the Cancer Treatment Centers of America (CTCA). Patients with a diagnosis of metastatic breast with lung or liver metastases, and treated with eribulin, gemcitabine, or capecitabine as third-line therapy were included in the analysis. Landmark survival was calculated as percentage of patients alive at 6, 12, 24, and 36\u00a0months. Overall survival was compared between treatment arms within TNBC and HR+\/HER2\u2212 using log-rank analysis. Cox regression analyses was performed to estimate hazard ratios for comparison of treatments within TNBC and HR+\/HER2\u2212 subtype.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>443 patients with liver or lung metastases received third-line therapy with eribulin (<jats:italic>n<\/jats:italic>\u2009=\u2009229), gemcitabine (<jats:italic>n<\/jats:italic>\u2009=\u2009134), or capecitabine (<jats:italic>n<\/jats:italic>\u2009=\u200980). Eribulin patients had a higher percentage of patients alive at all landmark timepoints vs. gemcitabine, and a higher percentage of patients alive until 36\u00a0months vs. capecitabine. Median survival times showed that overall, and within the TNBC and HR+\/HER2\u2212 subtype, patients receiving eribulin had a numerically higher median overall survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This real-world evidence study is consistent with randomized clinical trial data and demonstrates consistency of eribulin effectiveness in MBC patients with lung or liver metastases overall and in TNBC and HR+\/HER2\u2212 disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-020-05867-0","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T19:02:32Z","timestamp":1597690952000},"page":"559-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-2965","authenticated-orcid":false,"given":"Shayma","family":"Kazmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjana","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dheeraj","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"5867_CR1","unstructured":"National Cancer Institute (2019) Cancer stat facts: female breast cancer. Surveillance E, and End Results Program. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed 10 Sept 2019"},{"issue":"Suppl 3","key":"5867_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","volume":"10","author":"J O'Shaughnessy","year":"2005","unstructured":"O'Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20\u201329. https:\/\/doi.org\/10.1634\/theoncologist.10-90003-20","journal-title":"Oncologist"},{"issue":"4","key":"5867_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/jncics\/pky062","volume":"2","author":"JL Caswell-Jin","year":"2018","unstructured":"Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW (2018) Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr 2(4):62. https:\/\/doi.org\/10.1093\/jncics\/pky062","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"5867_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10549-015-3352-0","volume":"150","author":"CD Savci-Heijink","year":"2015","unstructured":"Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J, van de Vijver MJ (2015) Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat 150(3):547\u2013557. https:\/\/doi.org\/10.1007\/s10549-015-3352-0","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5867_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","volume":"161","author":"X Li","year":"2017","unstructured":"Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA, Meisel JL (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279\u2013287. https:\/\/doi.org\/10.1007\/s10549-016-4059-6","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5867_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3816\/CBC.2010.n.009","volume":"10","author":"DA Yardley","year":"2010","unstructured":"Yardley DA (2010) Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer 10(1):64\u201373. https:\/\/doi.org\/10.3816\/CBC.2010.n.009","journal-title":"Clin Breast Cancer"},{"key":"5867_CR7","unstructured":"National Comprehensive Cancer Network in Oncology Breast Cancer (2020) Version 2.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 26 Feb 2020"},{"key":"5867_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-0896(16)06001-1","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, Colleoni M, Di Leo A et al (2016) Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice. Cancer Treat Commun. https:\/\/doi.org\/10.1016\/s2213-0896(16)06001-1","journal-title":"Cancer Treat Commun"},{"key":"5867_CR9","volume-title":"Halaven (eribulin mesylate) [package insert]","author":"Eisai lnc.","year":"2017","unstructured":"Eisai lnc. (2017) Halaven (eribulin mesylate) [package insert]. Eisai Inc., Woodcliff Lake"},{"key":"5867_CR10","volume-title":"Gemzar (gemcitabine) [package insert]","author":"Lilly USA, Inc.","year":"2019","unstructured":"Lilly USA, Inc. (2019) Gemzar (gemcitabine) [package insert]. Lilly USA, Inc., Indianapolis"},{"key":"5867_CR11","volume-title":"Xeloda (capecitabine) [package insert]","author":"Genentech","year":"2019","unstructured":"Genentech (2019) Xeloda (capecitabine) [package insert]. Genentech, South San Francisco"},{"key":"5867_CR12","volume-title":"Tykerb (lapatinib) [package insert]","author":"Novartis","year":"2018","unstructured":"Novartis (2018) Tykerb (lapatinib) [package insert]. Novartis, East Hanover"},{"issue":"8","key":"5867_CR13","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","volume":"27","author":"X Pivot","year":"2016","unstructured":"Pivot X, Marm\u00e9 F, Koenigsberg R, Guo M, Berrak E, Wolfer A (2016) Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 27(8):1525\u20131531. https:\/\/doi.org\/10.1093\/annonc\/mdw203","journal-title":"Ann Oncol"},{"issue":"6","key":"5867_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/jco.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594\u2013601. https:\/\/doi.org\/10.1200\/jco.2013.52.4892","journal-title":"J Clin Oncol"},{"issue":"9","key":"5867_CR15","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1002\/cam4.1705","volume":"7","author":"SS Mougalian","year":"2018","unstructured":"Mougalian SS, Copher R, Kish JK, McAllister L, Wang Z, Broscious M, Garofalo D, Radtchenko J, Feinberg BA (2018) Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: long-term outcomes of patients treated in the US community oncology setting. Cancer Med 7(9):4371\u20134378. https:\/\/doi.org\/10.1002\/cam4.1705","journal-title":"Cancer Med"},{"key":"5867_CR16","unstructured":"Eribulin Summary of Product Characteristics (SmPC). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/halaven-epar-product-information_en.pdf"},{"key":"5867_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40064-016-1700-0","volume":"5","author":"O Garrone","year":"2016","unstructured":"Garrone O, Montemurro F, Saggia C, La Verde N, Vandone AM, Airoldi M, De Conciliis E, Donadio M, Lucio F, Polimeni MA, Oletti MV, Giacobino A, Merlano MC (2016) Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life. SpringerPlus 5:59\u201359. https:\/\/doi.org\/10.1186\/s40064-016-1700-0","journal-title":"SpringerPlus"}],"updated-by":[{"DOI":"10.1007\/s10549-021-06223-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000}}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05867-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:29:41Z","timestamp":1629160181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05867-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["5867"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05867-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10549-021-06223-6","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"7 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10549-021-06223-6","URL":"https:\/\/doi.org\/10.1007\/s10549-021-06223-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}